IDEAYA Advances Cancer Pipeline with Biocytogen’s Bispecific ADC, Targeting B7H3/PTK7

Partnership and Licensing:
IDEAYA Biosciences has exercised its option for an exclusive worldwide license from Biocytogen Pharmaceuticals for the B7H3/PTK7 bispecific antibody-drug conjugate (BsADC) program, IDE0344.

Development Candidate:
IDE034 has been nominated as a development candidate, a potential first-in-class B7H3/PTK7 topo-I-payload BsADC, demonstrating robust monotherapy tumor regressions in multiple preclinical models4.

Target Indications:
The B7H3/PTK7 BsADC targets solid tumors, including lung, colorectal, and head and neck cancers, where B7H3/PTK7 co-expression has been reported at approximately 30%, 46%, and 27%, respectively4.

Financial Terms:
IDEAYA will pay Biocytogen upfront and option exercise fees, along with additional development and regulatory milestone payments, commercial milestone payments, and royalties on net sales, totaling $406.5 million4.

Clinical Timeline:
IDEAYA aims to submit an Investigational New Drug (IND) application to the FDA in 2025 for IDE034, subject to satisfactory completion of ongoing preclinical and IND-enabling studies4.

Combination Therapy Potential:
IDE034 has the potential to be developed as a monotherapy and in combination with IDEAYA’s PARG inhibitor IDE1614.

Sources:

4. https://www.biospace.com/press-releases/ideaya-announces-development-candidate-nomination-of-ide034-a-potential-first-in-class-b7h3-ptk7-topo-i-payload-bispecific-adc-and-option-exercise-with-biocytogen